HAEM5:Breast implant-associated anaplastic large cell lymphoma: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 4: Line 4:
{{Under Construction}}
{{Under Construction}}


<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].
<blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].
}}</blockquote>
}}</blockquote>


Line 14: Line 14:


Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
__TOC__
==WHO Classification of Disease==
==WHO Classification of Disease==


Line 39: Line 36:
|}
|}


==Definition / Description of Disease==
==Related Terminology==
 
*Provisional entity in WHO 2016 classification
*Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoproliferative disorder that occurs in patients with breast implants.
*Belongs to the so-called triple negative category of systemic anaplastic large cell lymphomas (sALCL)<ref name=":1">{{Cite journal|last=N|first=Oishi|last2=Gs|first2=Brody|last3=Rp|first3=Ketterling|last4=Ds|first4=Viswanatha|last5=R|first5=He|last6=S|first6=Dasari|last7=M|first7=Mai|last8=Hk|first8=Benson|last9=Ca|first9=Sattler|date=2018|title=Genetic subtyping of breast implant-associated anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29921615/|language=en|doi=10.1182/blood-2017-12-821868|pmc=PMC6073323|pmid=29921615}}</ref>
 
==Synonyms / Terminology==
 
* Seroma-associated anaplastic large cell lymphoma
 
==Epidemiology / Prevalence==
 
*Rare (fewer than 1 in 100,000 with implants)<ref name=":2">{{Cite journal|last=Gs|first=Brody|last2=D|first2=Deapen|last3=Cr|first3=Taylor|last4=L|first4=Pinter-Brown|last5=Sr|first5=House-Lightner|last6=Js|first6=Andersen|last7=G|first7=Carlson|last8=Mg|first8=Lechner|last9=Al|first9=Epstein|date=2015|title=Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases|url=https://pubmed.ncbi.nlm.nih.gov/25490535/|language=en|pmid=25490535}}</ref>
*No association with type of implant (silicone vs. saline, textured vs. smooth)<ref name=":2" />
*Median time to lymphoma diagnosis after implant is 8-9 years<ref name=":2" />
*Mean age 50<ref name=":2" />
 
==Clinical Features==
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
{| class="wikitable"
|'''Signs and Symptoms'''
|<span class="blue-text">EXAMPLE:</span> Asymptomatic (incidental finding on complete blood counts)
 
<span class="blue-text">EXAMPLE:</span> B-symptoms (weight loss, fever, night sweats)
 
<span class="blue-text">EXAMPLE:</span> Fatigue
 
<span class="blue-text">EXAMPLE:</span> Lymphadenopathy (uncommon)
|-
|'''Laboratory Findings'''
|<span class="blue-text">EXAMPLE:</span> Cytopenias
 
<span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level)
|}
 
 
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>
 
*Pain, swelling around implant<ref name=":3">{{Cite journal|last=D|first=Lazzeri|last2=T|first2=Agostini|last3=G|first3=Bocci|last4=G|first4=Giannotti|last5=G|first5=Fanelli|last6=Ag|first6=Naccarato|last7=R|first7=Danesi|last8=M|first8=Tuccori|last9=M|first9=Pantaloni|date=2011|title=ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity|url=https://pubmed.ncbi.nlm.nih.gov/21729665/|language=en|pmid=21729665}}</ref>
*Peri-implant effusion most common (approximately 80% cases)<ref name=":3" />
*Axillary lymphadenopathy<ref name=":3" />
*Extracapsular extension to form a solid mass of tumor cells possible<ref name=":3" />
 
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Sites of Involvement==
 
*Peri-implant (Stage I)
*Extracapsular dissemination not uncommon
 
==Morphologic Features==
 
*Large, pleomorphic<ref name=":0">{{Cite journal|last=Rn|first=Miranda|last2=Tn|first2=Aladily|last3=Hm|first3=Prince|last4=R|first4=Kanagal-Shamanna|last5=D|first5=de Jong|last6=Le|first6=Fayad|last7=Mb|first7=Amin|last8=N|first8=Haideri|last9=G|first9=Bhagat|date=2014|title=Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients|url=https://pubmed.ncbi.nlm.nih.gov/24323027/|language=en|doi=10.1200/JCO.2013.52.7911|pmc=PMC4062709|pmid=24323027}}</ref><ref name=":4">{{Cite journal|last=Sh|first=Swerdlow|last2=E|first2=Campo|last3=Sa|first3=Pileri|last4=Nl|first4=Harris|last5=H|first5=Stein|last6=R|first6=Siebert|last7=R|first7=Advani|last8=M|first8=Ghielmini|last9=Ga|first9=Salles|date=2016|title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms|url=https://pubmed.ncbi.nlm.nih.gov/26980727/|language=en|doi=10.1182/blood-2016-01-643569|pmc=PMC4874220|pmid=26980727}}</ref>
*Hallmark cells<ref name=":0" /><ref name=":4" />
 
==Immunophenotype==
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
 
{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (universal)||<span class="blue-text">EXAMPLE:</span> CD1
|-
|Positive (subset)||<span class="blue-text">EXAMPLE:</span> CD2
|-
|Negative (universal)||<span class="blue-text">EXAMPLE:</span> CD3
|-
|Negative (subset)||<span class="blue-text">EXAMPLE:</span> CD4
|}
 
 
<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}}</blockquote>
 
{| class="wikitable sortable"
|-
!Finding<ref name=":1" /><ref>{{Cite journal|last=Ae|first=Quesada|last2=Lj|first2=Medeiros|last3=Mw|first3=Clemens|last4=Mc|first4=Ferrufino-Schmidt|last5=S|first5=Pina-Oviedo|last6=Rn|first6=Miranda|date=2019|title=Breast implant-associated anaplastic large cell lymphoma: a review|url=https://pubmed.ncbi.nlm.nih.gov/30206414/|language=en|pmid=30206414}}</ref>!!Marker
|-
|Positive (universal)||CD30
|-
|Positive (frequent)
|Varying pan T-cell antigen expression (CD3, CD2, CD5, CD7, CD4, CD8), MUM1
|-
|Negative (universal)||ALK
|}


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==WHO Essential and Desirable Genetic Diagnostic Criteria==
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
{| class="wikitable"
|+
|WHO Essential Criteria (Genetics)*
|
|-
|WHO Desirable Criteria (Genetics)*
|
|-
|Other Classification
|
|}
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
==Related Terminology==
<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
{| class="wikitable"
{| class="wikitable"
|+
|+
|Acceptable
|Acceptable
|
|Seroma-associated anaplastic large cell lymphoma
|-
|-
|Not Recommended
|Not Recommended
|
|N/A
|}
|}


Line 221: Line 110:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>


*Not described
*Not described
Line 231: Line 120:




<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
* Chromosomal Rearrangements (Gene Fusions)
* Chromosomal Rearrangements (Gene Fusions)
* Individual Region Genomic Gain/Loss/LOH
* Individual Region Genomic Gain/Loss/LOH
Line 254: Line 143:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" /><blockquote class="blockedit">
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0">{{Cite journal|last=Rn|first=Miranda|last2=Tn|first2=Aladily|last3=Hm|first3=Prince|last4=R|first4=Kanagal-Shamanna|last5=D|first5=de Jong|last6=Le|first6=Fayad|last7=Mb|first7=Amin|last8=N|first8=Haideri|last9=G|first9=Bhagat|date=2014|title=Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients|url=https://pubmed.ncbi.nlm.nih.gov/24323027/|language=en|doi=10.1200/JCO.2013.52.7911|pmc=PMC4062709|pmid=24323027}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
----
Line 268: Line 157:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
Line 318: Line 207:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>


*N/A
*N/A
Line 334: Line 223:
!Chromosomal Pattern
!Chromosomal Pattern
!Molecular Pathogenesis
!Molecular Pathogenesis
!'''Prevalence -'''
!Prevalence -  
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|<span class="blue-text">EXAMPLE:</span>
Line 364: Line 253:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>


*N/A
*N/A
Line 378: Line 267:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  '''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>''EGFR''
|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 420: Line 309:
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote>


*JAK1 and STAT3 mutation (variable pattern leads to activation)<ref>{{Cite journal|last=P|first=Blombery|last2=Er|first2=Thompson|last3=K|first3=Jones|last4=Gm|first4=Arnau|last5=S|first5=Lade|last6=Jf|first6=Markham|last7=J|first7=Li|last8=A|first8=Deva|last9=Rw|first9=Johnstone|date=2016|title=Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27198716/|language=en|doi=10.3324/haematol.2016.146118|pmc=PMC5060038|pmid=27198716}}</ref><ref>{{Cite journal|last=A|first=Di Napoli|last2=P|first2=Jain|last3=E|first3=Duranti|last4=E|first4=Margolskee|last5=W|first5=Arancio|last6=F|first6=Facchetti|last7=B|first7=Alobeid|last8=F|first8=Santanelli di Pompeo|last9=M|first9=Mansukhani|date=2018|title=Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A|url=https://pubmed.ncbi.nlm.nih.gov/27859003/|language=en|pmid=27859003}}</ref>
*JAK1 and STAT3 mutation (variable pattern leads to activation)<ref>{{Cite journal|last=P|first=Blombery|last2=Er|first2=Thompson|last3=K|first3=Jones|last4=Gm|first4=Arnau|last5=S|first5=Lade|last6=Jf|first6=Markham|last7=J|first7=Li|last8=A|first8=Deva|last9=Rw|first9=Johnstone|date=2016|title=Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27198716/|language=en|doi=10.3324/haematol.2016.146118|pmc=PMC5060038|pmid=27198716}}</ref><ref>{{Cite journal|last=A|first=Di Napoli|last2=P|first2=Jain|last3=E|first3=Duranti|last4=E|first4=Margolskee|last5=W|first5=Arancio|last6=F|first6=Facchetti|last7=B|first7=Alobeid|last8=F|first8=Santanelli di Pompeo|last9=M|first9=Mansukhani|date=2018|title=Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A|url=https://pubmed.ncbi.nlm.nih.gov/27859003/|language=en|pmid=27859003}}</ref>
Line 460: Line 349:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>
<blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>


*JAK/STAT activation<ref name=":5">{{Cite journal|last=Kim|first=Won Seog|date=2017-11-30|title=Faculty Opinions recommendation of Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.|url=http://dx.doi.org/10.3410/f.725957551.793539732}}</ref><ref name=":1" />
*JAK/STAT activation<ref name=":5">{{Cite journal|last=Kim|first=Won Seog|date=2017-11-30|title=Faculty Opinions recommendation of Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.|url=http://dx.doi.org/10.3410/f.725957551.793539732}}</ref><ref name=":1">{{Cite journal|last=N|first=Oishi|last2=Gs|first2=Brody|last3=Rp|first3=Ketterling|last4=Ds|first4=Viswanatha|last5=R|first5=He|last6=S|first6=Dasari|last7=M|first7=Mai|last8=Hk|first8=Benson|last9=Ca|first9=Sattler|date=2018|title=Genetic subtyping of breast implant-associated anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29921615/|language=en|doi=10.1182/blood-2017-12-821868|pmc=PMC6073323|pmid=29921615}}</ref>
*MYC/TP53 dysregulation<ref name=":5" /><ref name=":1" />
*MYC/TP53 dysregulation<ref name=":5" /><ref name=":1" />


Line 480: Line 369:
==Additional Information==
==Additional Information==


* None
*None


==Links==
==Links==


* [[HAEM5:ALK-negative anaplastic large cell lymphoma]]
*[[HAEM5:ALK-negative anaplastic large cell lymphoma]]
* [[HAEM5:ALK-positive anaplastic large cell lymphoma]]
*[[HAEM5:ALK-positive anaplastic large cell lymphoma]]


==References==
==References==
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references />
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references />


'''
<br />


==Notes==
==Notes==
Line 499: Line 388:
          
          
<nowiki>*</nowiki>''Citation of this Page'': “Breast implant-associated anaplastic large cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Breast_implant-associated_anaplastic_large_cell_lymphoma</nowiki>.
<nowiki>*</nowiki>''Citation of this Page'': “Breast implant-associated anaplastic large cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Breast_implant-associated_anaplastic_large_cell_lymphoma</nowiki>.
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases B]]
[[Category:HAEM5]]
[[Category:DISEASE]]
[[Category:Diseases B]]